Thus, interference with TGF-β/Smad signaling via the manipulation of PGC-1α provides a promising approach for the development of therapeutic interventions for obesity and the metabolic syndrome [48]. This evidence concerns the gene PPARGC1A and obesity due to melanocortin 4 receptor deficiency.